These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34380538)

  • 21. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
    Zhang Z; Patel YT; Fiedler-Kelly J; Feng HP; Bruno CJ; Gao W
    J Clin Pharmacol; 2021 Feb; 61(2):254-268. PubMed ID: 32949031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Dillon RJ; Shorr AF
    BMC Infect Dis; 2022 Oct; 22(1):775. PubMed ID: 36199012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
    Pogue JM; Kaye KS; Veve MP; Patel TS; Gerlach AT; Davis SL; Puzniak LA; File TM; Olson S; Dhar S; Bonomo RA; Perez F
    Clin Infect Dis; 2020 Jul; 71(2):304-310. PubMed ID: 31545346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Wunderink RG; Roquilly A; Croce M; Rodriguez Gonzalez D; Fujimi S; Butterton JR; Broyde N; Popejoy MW; Kim JY; De Anda C
    Clin Infect Dis; 2021 Aug; 73(3):e710-e718. PubMed ID: 33720350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.
    Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
    Infect Dis Ther; 2021 Sep; 10(3):1227-1252. PubMed ID: 34278551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
    Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
    Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
    Roilides E; Ashouri N; Bradley JS; Johnson MG; Lonchar J; Su FH; Huntington JA; Popejoy MW; Bensaci M; De Anda C; Rhee EG; Bruno CJ
    Pediatr Infect Dis J; 2023 Apr; 42(4):292-298. PubMed ID: 36689671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis.
    Roilides E; Bradley JS; Lonchar J; Huntington JA; Wickremasingha P; Su FH; Bruno CJ; Johnson MG
    Microbiol Spectr; 2023 Sep; 11(5):e0180023. PubMed ID: 37698430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.
    Lucasti C; Hershberger E; Miller B; Yankelev S; Steenbergen J; Friedland I; Solomkin J
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5350-7. PubMed ID: 24982069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
    Hakeam HA; Askar G; Al Sulaiman K; Mansour R; Al Qahtani MM; Abbara D; Aldhayyan N; Dyab N; Afaneh L; Islami M; Al Duhailib Z
    J Infect Public Health; 2022 Oct; 15(10):1081-1088. PubMed ID: 36113401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
    Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
    Jackson CA; Newland J; Dementieva N; Lonchar J; Su FH; Huntington JA; Bensaci M; Popejoy MW; Johnson MG; De Anda C; Rhee EG; Bruno CJ
    Pediatr Infect Dis J; 2023 Jul; 42(7):557-563. PubMed ID: 37000942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 38. A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.
    Fernández-Cruz A; Alba N; Semiglia-Chong MA; Padilla B; Rodríguez-Macías G; Kwon M; Cercenado E; Chamorro-de-Vega E; Machado M; Pérez-Lago L; García de Viedma D; Díez Martín JL; Muñoz P
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
    Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
    Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
    Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
    J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.